Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer-Reference-Cited by-同舟云学术

Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

Published:2015-02 Issue:1 Volume:38 Page:74-79
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Makhoul Issam,Klimberg Vicki Suzanne,Korourian Soheila,Henry-Tillman Ronda S.,Siegel Eric R.,Westbrook Kent C.,Hutchins Laura F.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference30 articles.

1. . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.;Rastogi;J Clin Oncol,2008

2. . Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer.;Chollet;Br J Cancer,2002

3. . Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.;Guarneri;J Clin Oncol,2006

4. . Prognostic value of initial clinical disease stage after achieving pathological complete response.;Dawood;Oncologist,2008

5. . Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.;Yoshiji;Cancer Res,1996

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature;World Journal of Clinical Cases;2021-02-06

2. Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer;PLOS ONE;2020-04-16

3. The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?;Expert Review of Anticancer Therapy;2017-05-25

4. Novel therapeutic strategies for patients with triple-negative breast cancer;OncoTargets and Therapy;2016-10

5. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis;PLOS ONE;2016-08-31